Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRuiz Rodriguez, Juan Carlos
dc.contributor.authorMolnar, Zsolt
dc.contributor.authorDeliargyris, Efthymios N.
dc.contributor.authorFerrer Roca, Ricard
dc.date.accessioned2022-04-07T12:39:10Z
dc.date.available2022-04-07T12:39:10Z
dc.date.issued2021
dc.identifier.citationRuiz-Rodríguez JC, Molnar Z, Deliargyris EN, Ferrer R. The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences. Crit Care Res Pract. 2021;2021:7769516.
dc.identifier.issn2090-1313
dc.identifier.urihttp://hdl.handle.net/11351/7329
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; CytoSorb; Therapy
dc.description.abstractThe COVID-19 pandemic has led to the biggest global health crisis of our lifetime. There is accumulating evidence that a substantial number of critically ill COVID-19 patients exhibit a dysregulated host response manifesting as cytokine storm or cytokine release syndrome, which in turn contributes to the high observed rates of mortality. Just as in other hyperinflammatory conditions, extracorporeal cytokine removal may have potential beneficial effects in this subgroup of COVID-19 patients. The CytoSorb blood purification device is the most extensively investigated cytokine removal platform with considerable evidence suggesting that early intervention can provide rapid hemodynamic stabilization and improvement in vital organ functions. The purpose of this review is to provide an overview of the pathophysiological background of hyperinflammation in COVID-19 and to summarize the currently available evidence on the effects of hemoadsorption in these patients.
dc.language.isoeng
dc.publisherHindawi
dc.relation.ispartofseriesCritical Care Research and Practice;2021
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Mortalitat
dc.subjectCitocines - Purificació
dc.subjectProteïnes de la sang
dc.subject.meshHemadsorption
dc.subject.meshCytokines
dc.subject.mesh/adverse effects
dc.subject.meshCoronavirus Infections
dc.titleThe Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1155/2021/7769516
dc.subject.decshemadsorción
dc.subject.decscitocinas
dc.subject.decs/efectos adversos
dc.subject.decsinfecciones por Coronavirus
dc.relation.publishversionhttps://doi.org/10.1155/2021/7769516
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ruiz-Rodríguez JC, Ferrer R] Servei de Cures Intensives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Disfunció d'Òrgans de Xoc i Reanimació, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Molnar Z] CytoSorbents Europe GmbH, Berlin, Germany. Institute for Translational Medicine, School of Medicine, University of Pécs, Pécs, Hungary. Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland. Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary. [Deliargyris EN] CytoSorbents Corporation, Monmouth Junction, NJ, USA
dc.identifier.pmid34336280
dc.identifier.wos000683119800002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record